PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 30, 2023Cancers15 citationsOpen Access

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib

HJHeikki Joensuu

Key Points

Key points are not available for this paper at this time.

Abstract

mutations. Adjuvant imatinib improves OS substantially if high-risk GISTs can be identified, treatment duration is long enough, and GISTs harbor an imatinib-sensitive mutation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Heikki Joensuu (2023) studied this question.

synapsesocial.com/papers/6a078712beabdc12ba079c56https://doi.org/10.3390/cancers15153879
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial2023 · 27 citations
  2. 2Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world2022 · 25 citations
  3. 3Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors2000 · 1,286 citations
  4. 4Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up2021 · 600 citations
  5. 5Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts2011 · 1,018 citations